Abstract
In this study, a new class of furochromone derivatives bearing β-naphthol was synthesized via one-pot multicomponent reactions. First, condensation one mole of furochromone carbaldehyde (I) with two moles of β-naphthol afforded the corresponding Xanthene’ dye derivatives (II). A one-pot three-component reaction of (I), β-naphthol and urea or thiourea result in the formation of the corresponding oxazinones (IIIa, b). Moreover, reaction of (I) and β-naphthol with primary aromatic amines, heterocyclic amines or 2ry amines using triethyl amine as catalyst afforded the corresponding amino derivatives (IV–XIII). On the other hand, a one-pot three-component reaction of (I) and β-naphthol with active methylene compounds namely, malononitrile, propionitrile, diethylmalonate methyl propionate or diethyl succinate led to the formation of furochromone derivatives (VIV)–(XVIII). The antitumor activities of certain selected new compounds were screened, in vitro, against a panel of three (liver, HepG2; breast, MCF-7, HepG-2 and PC-3) human solid tumor cell lines as well as the normal cell line (human normal melanocyte, HFB4) in comparison to the known anticancer drug: 5-fluorouracil using MTT assay. Our results showed that the vast majority of the newly synthesized derivatives did not exert any activity against the growth of HFB4normal cell line. Compounds (IV), (XIIIa), and (XIIIb) revealed remarkable anticancer activity against MCF-7 cell line with IC50 5.4, 4.65, and 6.09 μg/mL respectively compared to 5-fluorouracil (IC50 = 4.7 μg/mL). Moreover, compounds (IIIb), (VII), (IX), and (XVI) showed potent activity against HepG-2 cancer cell line of IC50 ranging from 5.57 to 6.34 μg/mL. Compound (VII) revealed also anticancer activity against PC-3 cancer cell line with IC50 6.77 μg/mL vs. 5.05 for 5-fluorouracil. The inhibitory activity of the most active anti-proliferative compounds (IIIb), (IV), (VII), (IX), (XIIIa, b) and (XVI) against EGFR were studied. Compound (VII) showed the best inhibitory activity against EGFR with IC50 39.93 ng/ml in comparison to erlotinib (IC50 29.18 ng/mL). Molecular docking simulation was performed to position compounds (IIIb), (IV), (VII), (IX), (XIIIa, b), and (XVI) into the EGFR active site to determine the probable binding mode.
Similar content being viewed by others
REFERENCES
Cooper, G.M., The Cell: A Molecular Approach, Sunderland, MA: Sinauer Associates, The Development and Causes of Cancer, 2000, 2nd ed. https://www.ncbi. nlm.nih.gov/books/NBK9963.
Schirrmacher, V., Int. J. Oncol., 2019, vol. 54, pp. 407–419. https://doi.org/10.3892/ijo.2018.4661
Szumilak, M., Wiktorowska-Owczarek, A., and Stanczak, A., Molecules, 2021, vol. 26, p. 2601. https://doi.org/10.3390/molecules26092601
Elgazwy, A.S.H., Edrees, M.M., and Ismail, N.S.M., J. Enzyme Inhib. Med. Chem., 2013, vol. 28, pp. 1171–1181. https://doi.org/10.3109/14756366.2012.719504
Le, Y., Gan, Y., Fu, Y., Liu, J., Li, W., Zou, X., Zhou, Z., Wang, Z., Ouyang, G., and Yan, L., J. Enzyme Inhib. Med. Chem., 2020, vol. 35, pp. 555–564. https://doi.org/10.1080/14756366.2020.1715389
Chang, S.C., Lai, Y.C., Chang, C.Y., Huang, L.K., Chen, S.J., Tan, K.T., Yu, P.N., and Lai, J.I., Transl. Oncol., 2019, vol. 12, pp. 1425–1431. https://doi.org/10.1016/j.tranon.2019.07.008
Gan, Y., Shi, C., Inge, L., Hibner, M., Balducci, J. and Huang. Y., Oncogene, 2010, vol. 29, pp. 4947–4958. https://doi.org/10.1038/onc.2010.240
Barker, A.J., Gibson, K.H., Grundy, W., Godfrey, A.A., Barlow, J.J., Healy, M.P., Woodburn, J.R., Ashton, S.E., Curry, B.J., Scarlett, L., Henthorn, L. and Richards, L., Bioorg. Med. Chem. Lett., 2001, 11, 1911–1914. https://doi.org/10.1016/s0960-894x(01)00344-4
Higgins, B., Kolinsky, K., Smith, M., Beck, G., Rashed, M., Adames, V., Linn, M., Wheeldon E, Gand, L., Birnboeck, H., and Hoffmann, G., Anticancer Drugs, 2004, vol. 15, pp. 503–512. https://doi.org/10.1097/01.cad.0000127664.66472.60
Sequist, L. V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Bergethon, K., Shaw, A.T., Gettinger, S., Cosper, A.K., Akhavanfard, S., Heist, R.S., Temel, J., Christensen, J.G., Wain, J.C., Lynch, T.J., Vernovsky, K., Mark, E.J., Lanuti, M., Iafrate, A.J., Mino-Kenudson, M., and Engelman, J.A., Sci. Translat. Med., 2011, vol. 3, pp. 75–101. https://doi.org/10.1126/scitranslmed.3002003
Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S.E., Cantarini, M., Barrett, J.C., Jänne, P.A. and Oxnard, G.R., Nat. Med., 2015, vol. 21, pp. 560–562. https://doi.org/10.1038/nm.3854
Franchi, G.G., Bovalini, L., Martelli, P., Ferri, S. and Sbardellati, E., J. Ethnopharmacol., 1985, vol. 14, pp. 203–212. https://doi.org/10.1016/0378-8741(85)90088-1
Ullrich, A. and Schlessinger, J., Cell, 1990, vol. 61, pp. 203–212. https://doi.org/10.1016/0092-8674(90)90801-k
Hubbard, S.R. and Till, J.H., Annu. Rev. Biochem., 2000, vol. 69, pp. 373–398. https://doi.org/10.1146/annurev.biochem.69.1.373
Dai, Y., Guo, Y., Frey, R.R., Ji, Z., Curtin, M.L., Ahmed A.A., Albert, D.H., Arnold, L., Arries S.S., Barlozzari, T., Bauch, J.L., Bouska, J.J., P.F. Bousquet, Cunha, G.A., Glaser, K.B., Guo, J., Li, J., Marcotte, P.A., Marsh, K.C., Moskey, M.D., Pease, L.J., Stewart, K.D., Stoll,V.S., Tapang, P., Wishart, N., Davidsen, S.K., and Michaelides, M.R. J. Med. Chem., 2005, vol. 48, pp. 6066–6083. https://doi.org/10.1021/jm050458h
Chaudhary, A., Mol. Diversity, 2021, vol. 25, pp. 1211–1245. https://doi.org/10.1007/s11030-020-10076-4
Nishiyama, T., Sakita, K., Fuchigami, T., and Tsutomu, F.T., Polym. Degrad. Stab., 1998, vol. 62, pp. 529–534. https://doi.org/10.1016/S0141-3910(98)0038-X
Zelefack, F., Guilet, D., Fabre, N., Bayet, C., Chevalle, S., Ngouela, S., Lenta, B. N., Valentin, A., Tsamo, E., and Dijoux-Franca, M.G., J. Nat. Prod., 2009, vol. 72, pp. 954–957.
Wan, Y., Wang, C., Wang, H., Zhao, L., Zhang, X., Shi, J., and Wu, H., J. Heterocycl. Chem., 2014, vol. 51, pp. 1293–1297. https://doi.org/10.1002/jhet.1658
Bhattacharjee, S., Gattu, R., and Khan, A.T., Chem. Select., 2018, vol. 3, pp. 4760–4763. https://doi.org/10.1002/slct.201800372
Devi, K.M., Chanu, L.G., Chanu, I.S., and Singh, O.M., Lett. Org. Chem., 2014, vol. 11, pp. 743–747.
Mathew, B.P., Kumar, A., Sharma, S., and Shukla, P.K., Eur. J. Med. Chem., 2010, vol. 45, pp. 1502–1507. https://doi.org/10.1016/j.ejmech.2009.12.058
Vahabinia, H.R., Karami, B., and Khodabakhshi, S., J. Chin. Chem. Soc., 2013, vol. 60, pp. 1323–1327. https://doi.org/10.1002/jccs.201300126
Singh, M., Nandi, G., and Samai, S., Synlett., 2010, vol. 7, pp. 1133–1137. https://doi.org/10.1055/s-0029-1219574
Zhi, S., Ma, X., and Zhang, W., Org. Biomol. Chem., 2019, vol. 17, pp. 7632–7650. https://doi.org/10.1039/C9OB00772E
Barra, I.A., Islas-Jácome, A., and González-Zamora, E., Org. Biomol. Chem., 2018, vol. 16, pp. 1402–1418. https://doi.org/10.1039/c7ob02305g
Shabir, G. and Saeed, A., J. Chil. Chem. Soc., 2016, vol. 61, pp. 2907–2912. https://doi.org/10.4067/S0717-97072016000200012
Cardellicchio, C., Capozzi, M.A.M., and Naso, F., Tetrahedron, 2010, vol. 21, pp. 507–517. https://doi.org/10.1016/j.tetasy.2010.03.020
Stamos, J., Sliwkowski, M.X., and Eigenbrot, C., J. Biol. Chem., 2002, vol. 277, pp. 46265–46272. https://doi.org/10.1074/jbc.M207135200
Raymond, E., Faivre, S., and Armand, J.P., Drugs, 2000, vol. 60, pp. 15–23. https://doi.org/10.2165/00003495-200060001-00002
Nakamura, J.L., Expert Opin. Ther. Targets, 2007, vol. 11, pp. 463–472. https://doi.org/10.1517/14728222.11.4.463
ACKNOWLEDGMENTS
The authors are grateful to Dr. Esam Rashwan, Head of the confirmatory diagnostic unit VACSERA-EGYPT, for carrying out the enzyme assays.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
COMPLIANCE WITH ETHICAL STANDARDS
This article does not contain any studies involving human participants performed by any of the authors and does not contain any studies involving animals performed by any of the author.
Conflict of Interests
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Fawzy, N.M., Ahmed, K.M., Abo-Salem, H.M. et al. Novel Furochromone Derivatives of Potential Anticancer Activity Targeting EGFR Tyrosine Kinase. Synthesis and Molecular Docking Study. Russ J Bioorg Chem 48, 749–767 (2022). https://doi.org/10.1134/S1068162022040082
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1068162022040082